The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy

Maria Francesca Tepedino1, Francesco Diana2,3, Filomena Abate1

  • 1Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via Allende, 84131, Baronissi, Salerno, Italy.

Journal of Neurology
|September 2, 2024
PubMed

Insights

White matter hyperintensities (WMH) in Progressive Supranuclear Palsy (PSP) may indicate neurodegeneration rather than vascular disease. WMH severity correlated with PSP clinical scores and wheelchair use, but not with cardiovascular risk factors.

Area of Science:

  • Neuroimaging
  • Neurology
  • Cerebrovascular Diseases

Background:

  • White matter hyperintensities (WMH) are MRI biomarkers for cerebral small vessel disease.
  • Their clinical significance in neurodegenerative disorders like Progressive Supranuclear Palsy (PSP) remains unclear.

Purpose of the Study:

  • To investigate WMH distribution in PSP compared to Parkinson's disease (PD).
  • To explore the impact of WMH on PSP clinical features.

Main Methods:

  • Sixty PSP and 33 PD patients underwent MRI.
  • Age-Related White Matter Changes (ARWMC) scores assessed WMH severity.
  • Correlations and regression analyses examined relationships between ARWMC and clinical data.

Main Results:

  • 68% of PSP patients had WMH, predominantly mild and fronto-parietal.
  • WMH severity correlated with PSP rating scale scores and wheelchair use.
  • No association found between WMH and cardiovascular risk factors or disease severity in PSP.

Conclusions:

  • WMH in PSP may reflect neurodegenerative processes rather than solely vascular changes.
  • WMH characteristics did not significantly impact the PSP phenotype or differ from PD.